Join Us

September 2011 Research News

Save as Favorite
Sign in to receive recommendations (Learn more)

Avastin Plus Taxol May Help Treat Metastatic, Triple-Negative Disease
September 30, 2011
Some women diagnosed with triple-negative metastatic breast cancer benefit from a combination of Avastin and Taxol. Read more...

Adding Iniparib to Second, Third Chemo Regimen May Help Treat Metastatic, Triple-Negative Disease
September 29, 2011
A new analysis suggests that women diagnosed with triple-negative metastatic breast cancer that was previously treated benefited from adding iniparib to the second or third chemotherapy regimen. Read more...

Nexavar Offers No Benefits in Treating Advanced-Stage Disease
September 28, 2011
A small, early study suggests that Nexavar offers no benefits for advanced-stage breast cancer treatment. Read more...

Zometa Seems to Reduce Recurrence Risk of Early-Stage Breast Cancer
September 26, 2011
A study suggests that Zometa after surgery may reduce the risk of recurrence and improve overall survival in postmenopausal women diagnosed with early-stage breast cancer. Read more...

Chemo Plus Herceptin Can Put Metastatic, HER2-Positive Disease Into Remission
September 26, 2011
Some metastatic, HER2-positive breast cancers will respond to Herceptin for several years, suggesting that long-term remission is possible. Read more...

Giving Chemo and Radiation Therapy at Same Time Offers Same Benefits as Sequential Timing
September 25, 2011
In a study of women who'd been diagnosed with early breast cancer, local recurrence happened 35% less often in those who were treated with chemotherapy and radiation at the same time rather than sequentially (one after the other). Read more...

Afinitor Added to Aromasin Slows Advanced-Stage Breast Cancer Growth
September 25, 2011
A study showed that postmenopausal women with advanced breast cancer who took Afinitor (chemical name: everolimus) with the aromatase inhibitor Aromasin (chemical name: exemestane) appeared to have longer progression-free survival compared to women taking Aromasin with a placebo. Read more...

Experimental T-DM1 May Help Treat Advanced-Stage, HER2-Positive Disease
September 25, 2011
In a preliminary study, women with HER2-positive locally advanced or metastatic breast cancer treated with the targeted therapy T-DM1 lived longer without the cancer showing signs of progression compared to similar women who received a standard treatment combination of Herceptin (chemical name: trastuzumab) and Taxotere (chemical name: docetaxel). Read more...

Prolia Approved by FDA to Treat Bone Loss in Women Taking Aromatase Inhibitor
September 19, 2011
The osteoporosis drug denosumab (Prolia) is now FDA-approved to treat bone loss in women taking aromatase inhibitors. Read more...

Worldwide Risk of Being Diagnosed with Breast Cancer Increasing
September 15, 2011
A new analysis of global trends over a 30-year span shows that breast and cervical cancers are on the rise. Read more...

“Personality” of Cancer Affects Recurrence Risk After Lumpectomy, Not When Chemo is Given
September 13, 2011
A study has found that cancer characteristics, not the timing of chemotherapy, affect the risk of recurrence in women diagnosed with early-stage breast cancer who had lumpectomy. Read more...

Women with Disease Linked to Abnormal Breast Cancer Gene Are Younger When Diagnosed Compared to Previous Generation
September 12, 2011
Research suggests that women diagnosed with breast or ovarian cancer linked to an inherited abnormal breast cancer are younger when diagnosed compared to their older relatives. Read more...

Internal Mammary Lymph Node Radiation Doesn’t Lower Recurrence Risk
September 12, 2011
Research suggests that internal mammary node radiation for women diagnosed with early-stage breast cancer that is large and/or has spread to the lymph nodes doesn't reduce recurrence risk or improve survival. Read more...

Study Supports Mammograms and Breast Self-Exams Starting at 40
September 9, 2011
A large study offers more evidence that annual mammograms benefit all women, including women 40 to 50 years old. Read more...

Tykerb Alone Doesn’t Work as Well as Herceptin Alone to Treat Early-Stage, HER2-Positive Disease
September 9, 2011
Early results from the ALTTO study show that Tykerb doesn't work as well as Herceptin when given alone after surgery to treat early-stage, HER2-positive breast cancer. Read more...

No Difference in Prognosis with Sentinel Node Biopsy Versus Axillary Node Biopsy
September 9, 2011
Research shows that women who had sentinel node biopsy did just as well as women who had axillary node biopsy, even though small clusters of breast cancer cells may have been in the axillary lymph nodes of the women who had sentinel node biopsy. Read more...

Online Tool May Help Predict Lymphedema Risk
September 8, 2011
A new online tool does a good job of predicting the risk of lymphedema after breast cancer surgery. Read more...

Lumpectomy and Radiation Therapy as Good as Mastectomy for Younger Women
September 7, 2011
Research shows that young women who had lumpectomy followed by radiation therapy were no more likely to have the breast cancer come back and just as likely to survive breast cancer as young women who had mastectomy. Read more...

Most Women with Early-Stage Breast Cancer Benefit from Treatments After Surgery
September 4, 2011
Research suggests that that most women diagnosed with early-stage breast cancer are likely to benefit from chemotherapy, hormonal therapy, and/or targeted therapy after surgery. Read more...

FDA Warning: Reclast May Cause Severe Kidney Problems
September 1, 2011
On Sept. 1, 2011 the U.S. Food and Drug Administration warned doctors and patients that Reclast may cause severe kidney problems. Read more...

Was this article helpful? Yes / No
Rn icon

Can we help guide you?

Create a profile for better recommendations

How does this work? Learn more
Are these recommendations helpful? Take a quick survey

Fy22oct sidebarad v02
Back to Top